Long-term Study in Chronic Kidney Disease (Extension From Study 14817)

Status Completed

Clinical Trial Summary

The objective of this study is to investigate the safety and the effect on reduction of serum phosphate of long-term administration of lanthanum carbonate (BAY77-1931) 750 to 2250 mg in patients with hyperphosphatemia who completed the 8 week double-blind treatment period of Study 14817 and are judged to be eligible for the long-term extension study.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01187628
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 3
Start date	September 2010
Completion date	April 2013

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT02237534` - Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia	Phase 4
Unknown status	`NCT01245517` - The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient	N/A
Completed	`NCT01252771` - Phosphate Kinetic Modeling 2	Phase 4
Completed	`NCT00506441` - A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia	Phase 3
Recruiting	`NCT04440696` - To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder	Phase 1/Phase 2
Completed	`NCT01976572` - Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects	Phase 1
Completed	`NCT01742585` - A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis	Phase 3
Completed	`NCT01191255` - A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis	Phase 3
Completed	`NCT01003223` - Phosphate Kinetic Modeling	N/A
Completed	`NCT00505037` - A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis	Phase 2
Completed	`NCT00508885` - The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients	Phase 1/Phase 2
Completed	`NCT04551300` - A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients	Phase 2
Completed	`NCT01955876` - Fosrenol Post-marketing Surveillance in Japan	N/A
Completed	`NCT04579315` - Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease	N/A
Completed	`NCT03861247` - Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients	Phase 3
Terminated	`NCT01725113` - Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol	Phase 4
Recruiting	`NCT01238588` - The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan	N/A
Completed	`NCT00542815` - A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia	Phase 3
Completed	`NCT04549597` - Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia	Phase 4
Completed	`NCT04789876` - Effectiveness of The Phosphate Mobile App on Serum Phosphorus in Adult Hemodialysis Patients With Hyperphosphatemia	N/A